Royalty Pharma to Present at TD Cowen’s 46th Annual Health Care Conference
Royalty Pharma (Nasdaq: RPRX) will participate in a fireside chat at TD Cowen’s 46th Annual Health Care Conference on March 3, 2026 at 1:10 p.m. ET.
Rhea-AI Summary
Royalty Pharma (Nasdaq: RPRX) will participate in a fireside chat at TD Cowen’s 46th Annual Health Care Conference on March 3, 2026 at 1:10 p.m. ET. According to the company, the session will be webcast and archived for at least thirty days.
Investors can access the live webcast and archived replay via the company’s Events page.
Positive
- None.
Negative
- None.
Details
News Market Reaction – RPRX
On Feb 27, the first trading day after this news, RPRX closed 1.87% above the previous close.
Data tracked by StockTitan Argus for the Feb 27 session.
Key Figures
- Conference date
- March 3, 2026
- TD Cowen’s 46th Annual Health Care Conference appearance
- Start time
- 1:10 p.m. ET
- Scheduled time for Royalty Pharma fireside chat
- Archive duration
- 30 days
- Minimum period webcast will remain accessible
Historical Context
-
Reported strong Q4 and 2025 growth with detailed 2026 Portfolio Receipts guidance.
-
Announced timing and access details for Q4 and full‑year 2025 results call.
-
Outlined 2025 transaction activity, market share, growth metrics and 2026 milestones.
-
Committed up to $500M to support Teva’s TEV-’408 development in vitiligo and celiac.
-
Announced first‑quarter 2026 dividend of $0.235, a 6.8% increase versus prior quarter.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 46th Annual Health Care Conference on March 3, 2026 at 1:10 p.m. ET.
The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 20 development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
ir@royaltypharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.